Article
AstraZeneca and IQVIA Partner on Potential COVID-19 Vaccine
Author(s):
The project will focus on providing a faster route to clinical studies for AstraZeneca’s potential COVID-19 vaccine, AZD1222.
AstraZeneca and IQVIA, a Durham, NC-based advanced analytics and technology solutions provider, announced they are teaming up to develop a potential new vaccine for COVID-19 as part of the US government’s Operation Warp Speed project.
The project will focus on providing a faster route to clinical studies for AstraZeneca’s potential COVID-19 vaccine, AZD1222, according to a July 14, 2020 press release. The initiative will also include a subject study which will utilize IQVIA’s virtual trial solutions.
Source: IQVIA
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
